

AMENDMENT TO THE CLAIMS

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide, wherein the peptide is selected from the group consisting of D-Pro D-Tyr D-Val, and D-Leu D-Thr D-Val, and wherein ~~the peptide further contains a modification selected from the group consisting of:~~
  - ~~—— (i) the C-terminal COOH group of the peptide is amidated;~~
  - ~~—— (ii) for D-Pro D-Tyr D-Val, the NH group is replaced with a COOH group, and~~
  - ~~—— (iii) for D-Leu D-Thr D-Val, the NH<sub>2</sub> groups is replaced with a COOH group.~~
2. (Original) The pharmaceutical composition of claim 1, being selected from the group consisting of a tablet, a powder, a granule, a pill and an injectable form.
3. (Original) The pharmaceutical composition of claim 2, which is an injectable form.
4. (Previously Presented) The pharmaceutical composition of claim 3, wherein said injectable form is selected from the group consisting of a solution, a suspension and an emulsion.
5. (Original) The pharmaceutical composition of claim 1, wherein the composition comprises from 1 to 100 mg of said peptide.
6. (Cancelled)
7. (Currently Amended) A food composition comprising a peptide, wherein the peptide is selected from the group consisting of D-Pro D-Tyr D-Val and D-Leu D-Thr D-Val, and wherein ~~the peptide further contains a modification selected from the group consisting of:~~
  - ~~—— (i) the C-terminal COOH group of the peptide is amidated;~~
  - ~~—— (ii) for D-Pro D-Tyr D-Val, the NH group is replaced with a COOH group, and~~

——(iii) for ~~D-Leu-D-Thr-D-Val~~, the  $\text{NH}_2$  groups is replaced with a  $\text{COOH}$  group.

8-15. (Cancelled)